Clinical Trials

GIST Patient Community Update on BLU-285 Clinical Program

Dr. Anthony Boral, Chief Medical Officer of Blueprint Medicines, provided an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation included an [...]

By |2020-07-09T14:57:35-04:00July 6th, 2017|Clinical Trials, Video|

Loxo Oncology Announces Plans for LOXO-101

In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. [...]

By |2020-02-21T15:03:40-05:00December 22nd, 2016|Clinical Trials, News, Research|

Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well

In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]

By |2018-10-30T09:41:06-04:00July 19th, 2016|Clinical Trials, News, Research|

Ignyta Announces Results for Potential New Cancer Treatment

Dr. Alexander Drilon of Memorial Sloan Kettering Cancer Center recently reported at AACR on a potential new cancer treatment, Entrectinib, a receptor tyrosine kinase (RTK) inhibitor developed to target tumors carrying NTRK1, NTRK2, NTRK3, [...]

By |2020-02-21T15:04:32-05:00July 12th, 2016|Clinical Trials, News, Research|

Update on Blueprint Medicines Clinical Trial for BLU-285

Recently a number of companies have begun to develop therapeutic options that target some of the rarer mutations in GIST. As there are currently no approved treatments specifically for these patients, this [...]

By |2019-07-03T10:45:21-04:00May 24th, 2016|Clinical Trials, News, Research|

Memorial Sloan Kettering Cancer Center Announces Innovative Basket Study

Memorial Sloan Kettering Cancer Center (MSKCC) recently announced results from a "basket study," an innovative clinical trial design that studies response to drugs based on specific mutations in patients' tumors rather than where the cancer originated.The [...]

By |2018-11-02T14:54:14-04:00August 26th, 2015|Clinical Trials, News, Research|

ASCO Recommends Expanding Clinical Trials to Include More Older Adults

A recent call to action from ASCO (American Society of Clinical Oncology) published in the Journal of Clinical Oncology recommends expanding clinical trials to include more older adults. Given that greater than 60% of cancers in [...]

By |2018-11-05T15:21:56-05:00July 23rd, 2015|Advocacy, Clinical Trials, News|
Go to Top